ArticleInternational urology and nephrology2016
Inhibiting malignant phenotypes of the bladder cancer cells by silencing long noncoding RNA SChLAP1.
Article in International urology and nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Epigenetic and Immunological Features of Bladder Cancer.International journal of molecular sciences · 2023Review
- Whole-genome-scale identification of novel non-protein-coding RNAs controlling cell proliferation and survival through a functional forward genetics strategy.Scientific reports · 2022Article
- Long Noncoding RNA Mediated Regulation in Human Embryogenesis, Pluripotency, and Reproduction.Stem cells international · 2022Review
- Long non‑coding RNA SChLAP1 regulates the proliferation of triple negative breast cancer cells via the miR‑524‑5p/HMGA2 axis.Molecular medicine reports · 2021Article
- Survival analysis of immune-related lncRNA in low-grade glioma.BMC cancer · 2019Article
- Long non-coding RNA expression in bladder cancer.Biophysical reviews · 2018Review
- Targeting RNA in mammalian systems with small molecules.Wiley interdisciplinary reviews. RNA · 2018Review
- Long Non-Coding RNA Cancer Susceptibility Candidate 2a (CASC2a) Is a Marker of Early Recurrence After Radical Cystectomy in Patients with Urothelial Carcinoma of the Bladder.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Long Noncoding RNA SChLAP1 Accelerates the Proliferation and Metastasis of Prostate Cancer via Targeting miR-198 and Promoting the MAPK1 Pathway.Oncology research · 2018Article
- Review
- Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets.International journal of molecular sciences · 2017Review
- Identification of long non-coding RNAs that stimulate cell survival in bladder cancer.Oncotarget · 2017Article
- Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression.Frontiers in oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesLong noncoding RNAs (lncRNAs) play key roles in process of cancer cell growth and apoptosis and have received increasing attention. SChLAP1 is a novel lncRNA that is required for development and progression of prostate cancer. We hypothesized that SChLAP1 also has important biological functions in human bladder cancer which is another type of urological cancer.
methodsThe expression of SChLAP1 in bladder cancer was determined using real-time qPCR. Bladder cancer T24 and 5637 cells were transfected with SChLAP1 siRNA or negative control siRNA. Cell proliferation, apoptosis and migration were determined using CCK-8 assay, flow cytometry analysis and wound healing assay, respectively.
resultsSChLAP1 was overexpressed in bladder cancer tissues compared to paired normal bladder tissues. Cell growth arrest, apoptosis induction and migration inhibition were also observed in bladder cancer T24 and 5637 cells after transfection with SChLAP1 siRNA.
conclusionsOur data suggest that SChLAP1 plays oncogenic roles and can be used as a therapeutic target for treating human bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.